PredictImmune appoints Aarti Gurnani as CEO

Predictimmune Ltd, developer of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, has appointed Aarti Gurnani as Chief Executive Officer.

Aarti joins PredictImmune after 25 years in leadership and commercial roles in the technology sector.  Having initially trained as an attorney in the US, she transitioned to industry where she led teams in finance, sales, marketing and strategy.  Most recently, she turned around Cisco’s EMEA telco service provider channel business, returning it to growth within in 18 months, and incubated a new channel organisation to capture the market transition to cloud and managed services.

Aarti Gurnani said: “It’s a huge honour to join the PredictImmune team as we approach the launch of our flagship PredictSURE IBD prognostic in the US in partnership with KSL Diagnostics.  Chronic autoimmune diseases like IBD represent one of the biggest healthcare challenges in the industrialised world.  PredictSURE IBD can dramatically improve quality of life and restore agency for people diagnosed with IBD by helping them select the right treatment for their individual disease profile early in the course of their disease.  I’d like to thank Andy Sandham and the Board of PredictImmune for placing their trust in me to lead Predictimmune in our mission to improve the lives of patients with IBD.”

Andy Sandham, Chairman, PredictImmune commented of the appointment said: “I am delighted to welcome Aarti to head up our leadership team as CEO; Aarti is a dynamic and versatile leader with a track record of delivering results in challenging environments and a strong background in scaling businesses through partners.  Her appointment signals a new beginning for PredictImmune as we expand our footprint to North America and look forward to the completion of our pivotal PROFILE study in the UK. “

Information for Patients

Information for Clinicians

Order a PredictSURE ® IBD test